Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer

NCT03872791 is registered in ClinicalTrials.gov with Jiangsu Alphamab Biopharmaceuticals Co., Ltd as lead sponsor.

NCT NCT03872791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03872791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer
Lead sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
May 30, 2019
Completion date
October 27, 2022
Enrollment
52 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer